OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DM58

Dental Corporation PCL

Healthcare Facilities & ServicesVerified

Dental Corporation PCL maintains a debt-to-equity ratio of 0.59, indicating a moderate level of leverage, and a current ratio of 1.37, suggesting adequate short-term liquidity to cover its obligations. The company's free cash flow of 26.47 million THB and operating cash flow of 48.77 million THB demonstrate its ability to generate positive cash from operations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Dental Corporation PCL reports a return on equity of 3.07% and a return on assets of 1.7%, which are below the industry benchmarks for healthcare facilities and services. These figures suggest that the company is not generating returns as efficiently as its peers. The operating margin, calculated as operating income of 27.94 million THB on revenue of 227.34 million THB, is 12.29%, which is in line with the industry average. The company's revenue is primarily concentrated in Thailand, with no significant international operations disclosed. The lack of geographic diversification may expose the company to local economic and regulatory risks. There are no disclosed segments beyond the primary dental services, indicating a single business line with no diversification in product or service offerings. Dental Corporation PCL's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The company's capital expenditure of -2.25 million THB indicates a reduction in investment in physical assets, which may affect its long-term growth potential. Analysts have provided a mean price target of 2.78 THB, with a single "hold" recommendation, suggesting limited upside potential in the near term. The company faces a medium liquidity risk due to its current ratio and negative net cash position. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. The risk assessment highlights the need for the company to manage its debt levels and maintain sufficient liquidity to support operations. Recent events include the publication of the latest financial results, which show a stable but not growing revenue base. There are no recent filings or transcripts indicating significant changes in strategy or operations.

30-day price · DM(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyDental Corporation PCL
TickerDM.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Dental Corporation PCL provides dental services and operates dental clinics in Thailand, generating revenue primarily through patient care and dental procedures.

Classification. Dental Corporation PCL is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Dental Corporation PCL maintains a debt-to-equity ratio of 0.59, indicating a moderate level of leverage, and a current ratio of 1.37, suggesting adequate short-term liquidity to cover its obligations. The company's free cash flow of 26.47 million THB and operating cash flow of 48.77 million THB demonstrate its ability to generate positive cash from operations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Dental Corporation PCL reports a return on equity of 3.07% and a return on assets of 1.7%, which are below the industry benchmarks for healthcare facilities and services. These figures suggest that the company is not generating returns as efficiently as its peers. The operating margin, calculated as operating income of 27.94 million THB on revenue of 227.34 million THB, is 12.29%, which is in line with the industry average. The company's revenue is primarily concentrated in Thailand, with no significant international operations disclosed. The lack of geographic diversification may expose the company to local economic and regulatory risks. There are no disclosed segments beyond the primary dental services, indicating a single business line with no diversification in product or service offerings. Dental Corporation PCL's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The company's capital expenditure of -2.25 million THB indicates a reduction in investment in physical assets, which may affect its long-term growth potential. Analysts have provided a mean price target of 2.78 THB, with a single "hold" recommendation, suggesting limited upside potential in the near term. The company faces a medium liquidity risk due to its current ratio and negative net cash position. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. The risk assessment highlights the need for the company to manage its debt levels and maintain sufficient liquidity to support operations. Recent events include the publication of the latest financial results, which show a stable but not growing revenue base. There are no recent filings or transcripts indicating significant changes in strategy or operations.
Key takeaways
  • Dental Corporation PCL has a moderate level of leverage and adequate short-term liquidity.
  • The company's return on equity and return on assets are below industry benchmarks.
  • Revenue is concentrated in Thailand, with no significant international operations.
  • Analysts have provided a mean price target of 2.78 THB, with a single "hold" recommendation.
  • The company's capital expenditure is negative, indicating a reduction in investment in physical assets.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$227.3M
Gross profit$82.5M
Operating income$27.9M
Net income$18.5M
R&D
SG&A
D&A
SBC
Operating cash flow$48.8M
CapEx-$2.3M
Free cash flow$26.5M
Total assets$1.09B
Total liabilities$488.2M
Total equity$603.4M
Cash & equivalents$56.9M
Long-term debt$355.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$528.5M-$9.8M-$24.2M-$6.3M
FY-3$814.6M$83.9M$57.5M$60.8M
FY-2$927.3M$108.7M$71.3M$66.8M
FY-1$954.4M$81.1M$50.5M$46.6M
FY0$1.05B$123.9M$85.8M$18.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.11B$451.4M$36.8M
FY-3$1.13B$537.2M$470.00
FY-2$1.07B$584.9M$49.0M
FY-1$1.33B$778.2M$40.6M
FY0$1.35B$833.1M$50.7M
PeriodOCFCapExFCFSBC
FY-4$34.4M-$15.5M-$6.3M
FY-3$103.6M-$14.0M$60.8M
FY-2$148.3M-$20.1M$66.8M
FY-1$103.8M-$8.5M$46.6M
FY0$161.6M-$78.7M$18.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$227.3M$27.9M$18.5M$26.5M
FQ-6$240.6M$23.6M$15.6M$23.1M
FQ-5$245.5M$18.5M$10.2M$3.3M
FQ-4$240.9M$11.0M$6.2M$14.4M
FQ-3$245.7M$23.9M$16.1M$10.4M
FQ-2$265.1M$28.9M$19.8M$14.8M
FQ-1$262.3M$28.9M$20.1M$4.6M
FQ0$273.9M$42.3M$29.9M$4.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.09B$603.4M$56.9M
FQ-6$1.11B$598.5M$48.5M
FQ-5$1.33B$772.0M$46.5M
FQ-4$1.33B$778.2M$40.6M
FQ-3$1.34B$794.2M$37.6M
FQ-2$1.31B$798.6M$21.7M
FQ-1$1.37B$818.7M$62.2M
FQ0$1.35B$833.1M$50.7M
PeriodOCFCapExFCFSBC
FQ-7$48.8M-$2.3M$26.5M
FQ-6$80.7M-$5.2M$23.1M
FQ-5$88.8M-$6.8M$3.3M
FQ-4$103.8M-$8.5M$14.4M
FQ-3$33.2M-$15.7M$10.4M
FQ-2$72.1M-$31.3M$14.8M
FQ-1$108.0M-$57.7M$4.6M
FQ0$161.6M-$78.7M$4.1M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$603.4M
Net cash-$298.6M
Current ratio1.4
Debt/Equity0.6
ROA1.7%
ROE3.1%
Cash conversion2.6%
CapEx/Revenue-1.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricDMActivity
Op margin12.3%5.6% medp25 -4.2% · p75 12.6%above median
Net margin8.1%2.8% medp25 -3.4% · p75 8.8%above median
Gross margin36.3%36.5% medp25 23.7% · p75 65.2%below median
CapEx / revenue-1.0%-4.9% medp25 -11.5% · p75 -2.0%top quartile
Debt / equity59.0%69.3% medp25 7.9% · p75 120.9%below median
Observations
IR observations
Mean price target2.78 THB
Median price target2.78 THB
High price target2.78 THB
Low price target2.78 THB
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Last actual EPS0.25 THB
Last actual revenue1,046,996,000 THB
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:01 UTC#5ec387b1
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 18:58 UTCJob: c51dddfd